北京市建国门北大街 8 号华润大厦 20 层 邮编：100005 电话：(86-10) 8519-1300 传真：(86-10) 8519-1350 junhebj@junhe.com 北京市君合律师事务所 关于金陵华软科技股份有限公司 2024 年度股东大会的法律意见书 致：金陵华软科技股份有限公司 北京市君合律师事务所（以下简称"本所"）接受金陵华软科技股份有限公司（以 下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》、中国证券监督管理委员会颁布实施的《上市公司股东会 规则》（以下简称"《股东会规则》"）等中国现行法律、行政法规和规范性文件（以 下简称"中国法律、法规"，为本法律意见书法律适用之目的，不包括中国香港特别 行政区、中国澳门特别行政区及台湾地区法律、法规）及《金陵华软科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，就公司 2024 年度股东大会（以 下简称"本次股东大会"）有关事宜出具本法律意见书。 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员的资 格、召集人资格、会议表决程序是否符合中国法律、法规 ...

Core Viewpoint - The company held its 2024 annual performance briefing, where it engaged with investors and addressed various inquiries regarding its business operations and future strategies [1] Group 1: Financial Performance - In 2024, the company achieved a revenue of 515 million yuan, a decrease of 6.55% compared to the previous year, primarily due to a decline in the food additive business and changes in the scope of consolidated financial statements [2] - The company reported a net profit decline, but the non-recurring net profit attributable to shareholders increased by 40.73% year-on-year [2][19] - For Q1 2025, the company recorded a revenue of 103 million yuan and a net loss of 22.72 million yuan, which represents a reduction in losses of 7.6% compared to the same period last year [18] Group 2: Research and Development - The company plans to invest 23.65 million yuan in R&D for 2024, accounting for 4.59% of total revenue, with a focus on downstream products of phosgene, pharmaceutical/agricultural intermediates, and electronic chemicals [2] - The company aims to enhance its market share in electronic chemicals, with revenues projected to grow from 18.53 million yuan in 2023 to 30.11 million yuan in 2024 [2] Group 3: Operational Strategies - The company is focusing on optimizing its product structure, expanding market reach, increasing R&D investment, and improving operational efficiency to enhance shareholder returns [8][10] - The management emphasizes the importance of solid business foundations and efficient operations as the basis for market value growth [10] Group 4: Business Direction and Challenges - The company is committed to its core business of fine chemical products, including paper chemicals, fluorescent whitening agents, and pharmaceutical/agricultural intermediates [20] - The company is facing challenges due to continuous losses over the past four years, but management is optimistic about improving profitability through various operational enhancements [19][12] Group 5: Corporate Governance and Shareholder Engagement - The company has a governance structure in place to ensure compliance with legal and regulatory requirements, and it is actively pursuing compensation for performance commitments related to a major shareholder [5][28] - The company has engaged with investors through a Q&A session, achieving a 100% response rate to inquiries, indicating a commitment to transparency and shareholder communication [1]

R&D Investment and Financial Performance - In 2024, the company plans to invest CNY 23.65 million in R&D, accounting for 4.59% of total revenue [2] - The company reported a revenue of CNY 515 million in 2024, a decrease of 6.55% compared to the previous year [3] - The net profit for Q1 2025 was CNY -22.72 million, a reduction in losses by 7.6% year-on-year [11] Market Strategy and Product Development - Future R&D will focus on downstream products of phosgene, pharmaceutical/agricultural intermediates, and electronic chemicals [2] - The company aims to increase its market share in electronic chemicals, with projected revenues of CNY 18.53 million in 2023 and CNY 30.11 million in 2024 [2] - The company is exploring new business growth points and optimizing asset structure to enhance competitiveness [6] Operational Challenges and Management Response - The company faced operational challenges due to a decline in the food additive business and changes in the consolidation scope from selling equity [3] - Management is implementing a "1+N" control strategy to reduce costs and improve efficiency, resulting in an increase in overall gross margin [3] - The company is actively pursuing legal action regarding performance compensation claims against a major shareholder [5] Corporate Governance and Future Outlook - The company has no current plans for stock issuance or major restructuring [12] - The management emphasizes the importance of solid business foundations and efficient operations for market value growth [6] - The company is committed to enhancing its governance structure and ensuring compliance with legal requirements [8] Industry Context and Competitive Landscape - The fine chemical industry is experiencing structural differentiation, with some sectors benefiting from high demand while others face cost pressures [13] - The company recognizes the importance of technological innovation and green transformation in navigating industry challenges [18]

Core Points - The company has completed the cancellation of certain stock options as part of its 2021 stock option incentive plan [1][2] - A total of 10.275 million stock options will be canceled due to the departure of 10 individuals and unmet performance conditions [2] Summary by Sections Reasons and Quantities for Cancellation - 116,100 stock options were canceled due to the departure of 9 individuals who were initial grant recipients and 1 individual from the reserved grant [1] - An additional 8.448 million stock options from the first grant and 666,000 from the reserved grant were canceled because the performance assessment conditions for the third exercise period were not met [2] - The total number of stock options canceled amounts to 10.275 million [2] Completion of Cancellation Process - The cancellation process has been confirmed and completed by the Shenzhen branch of China Securities Depository and Clearing Co., Ltd [2] - The completion of this cancellation does not affect the company's share capital and complies with relevant regulations [2]

证券代码：002453 证券简称：华软科技 公告编号：2025-021 金陵华软科技股份有限公司 关于部分股票期权注销完成暨 2021 年股票期权激励 计划实施完毕的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 金陵华软科技股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日召开第六届董事会第二十八次会议和第六届监事会第二十三次 会议，审议通过了《关于注销部分股票期权的议案》。具体内容详见 公司 2025 年 4 月 29 日于《中国证券报》《证券时报》《上海证券报》 和巨潮资讯网 www.cninfo.com.cn 披露的《关于注销部分股票期权的 公告》（公告编号：2025-015）。 近日公司已完成上述股票期权注销手续，具体内容如下： 一、本次注销的原因和数量 （一）根据《上市公司股权激励管理办法》和公司 2021 年股票 期权激励计划（以下简称"本激励计划"）的相关规定，鉴于本激励计 划首次授予的激励对象中 9 人已离职、预留授予的激励对象中 1 人已 离职，不再具备激励对象资格，其合计已获授但尚未行权的 116.1 万 份股票期权 ...

证券代码：002453 证券简称：华软科技 公告编号：2025-020 金陵华软科技股份有限公司 关于非公开发行限售股份解禁上市流通的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完 整，没有虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次申请解除限售股东共计 2 人，解除限售的股份数量合计 为 1,884,861 股，占目前公司总股本 812,367,126 的 0.2320%。 2、本次限售股份可上市流通日为 2025 年 5 月 14 日。 一、本次解除限售非公开发行股份的基本情况 （二）本次解除限售股份的股东认购情况 本次解除限售的股份为公司 2020 年 11 月向奥得赛化学原股东 发行的部分股份。本次解除限售股份股东 2020 年 11 月认购情况如 下： | 发行对象名称 | 发行股数（股） | | --- | --- | | 刘海然 | 144,989 | | 王军 | 1,739,872 | 二、本次申请解除股份限售股东做出的承诺及履行情况 本次申请解除股份限售股东刘海然及王军在发行中相关承诺如 下： （一）股份限售/锁定承诺 1、本人用于认购华软科技本次发行股份 ...

天风证券股份有限公司 关于金陵华软科技股份有限公司 发行股份及支付现金购买资产并募集配套资金 暨关联交易之部分限售股份解除限售的核查意见 天风证券股份有限公司（以下简称"天风证券""独立财务顾问"）作为金陵华软 科技股份有限公司（以下简称"华软科技""上市公司""公司"）发行股份及支付现 金购买资产并募集配套资金暨关联交易（以下简称"本次交易"）之独立财务顾问。 根据《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管理办法》 《深圳证券交易所股票上市规则》等有关法律法规和规范性文件的要求，对华软科 技本次交易中募集配套资金涉及的部分限售股份解除限售事项进行了认真、审慎的 核查，核查具体情况如下： 一、本次解除限售发行股份的基本情况 （一）股份发行情况 本次申请解除股份限售股东刘海然和王军在发行中承诺如下： 公司于 2020 年 9 月 18 日取得中国证券监督管理委员会（以下简称"中国证监 会"）于 2020 年 9 月 15 日印发的《关于核准金陵华软科技股份有限公司向吴细兵等 发行股份购买资产并募集配套资金的批复》（证监许可[2020]2233 号），核准公司该 次发行股份及支付现金购买资产 ...

证券代码：002453 证券简称：华软科技 公告编号：2025-019 金陵华软科技股份有限公司 关于公司债务人重整的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、 基本情况 2023 年 3 月，金陵华软科技股份有限公司（以下简称"公司"） 就与上海银嘉金融服务集团有限公司、金华永银商务服务合伙企业 （有限合伙）、金华银希商务服务合伙企业（有限合伙）、孔建国、 付临门支付有限公司（前述合称"被告"或"被执行人"）等之间股 权转让协议欠款纠纷案向北京市海淀区人民法院提起诉讼并申请财 产保全。具体内容详见公司 2023 年 5 月 22 日披露的《关于公司涉及 诉讼的公告》（公告编号：2023-049）。 2024 年 1 月，公司收到北京市海淀区人民法院送达的《民事调 解书》及《民事裁定书》，经北京市海淀区人民法院主持调解，各方 自愿达成调解协议。被执行人应支付公司股权转让本金 6,952 万元及 该款的违约金等。具体内容详见公司 2024 年 1 月 25 日披露的《关于 公司诉讼进展的公告》（公告编号：2024-005）。 《民事调解书》生效 ...

Financial Performance - The company's revenue for Q1 2025 was ¥103,307,169.44, a decrease of 18.62% compared to ¥126,944,021.88 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥22,724,505.20, an improvement of 7.60% from a loss of ¥24,593,709.34 in the previous year[5] - Net profit for the period was ¥-23,366,846.92, compared to ¥-25,381,069.65 in the previous period, showing an improvement of approximately 7.9%[20] - Total operating revenue decreased to ¥103,307,169.44 from ¥126,944,021.88, a decline of approximately 18.6%[18] - Total operating costs reduced to ¥127,160,318.34 from ¥152,875,730.79, representing a decrease of about 16.8%[18] - Total comprehensive income for the period was ¥-23,366,846.92, compared to ¥-25,381,069.65 in the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities was -¥8,685,624.45, representing a decline of 38.02% compared to -¥6,292,939.19 in Q1 2024[5] - Operating cash flow net amount was ¥-8,685,624.45, worsening from ¥-6,292,939.19 in the prior period[20] - Cash and cash equivalents at the end of the period stood at ¥125,294,103.00, down from ¥224,811,771.65[21] - Investment activities generated a net cash flow of ¥-40,431,288.97, compared to a positive cash flow of ¥39,475,348.55 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,660,327,442.55, down 2.23% from ¥1,698,204,909.31 at the end of the previous year[5] - Current assets totaled CNY 1,020,360,186.18, up from CNY 959,993,088.63 at the start of the period, indicating a growth of approximately 6.5%[14] - The company's cash and cash equivalents decreased to CNY 221,989,897.27 from CNY 292,725,257.12, reflecting a decline of about 24.1%[14] - Total liabilities decreased slightly to CNY 618,698,731.01 from CNY 633,698,136.30, showing a reduction of approximately 2.4%[16] - The company's total equity decreased to CNY 1,041,628,711.54 from CNY 1,064,506,773.01, representing a decline of about 2.1%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,436, with the largest shareholder holding 38.29% of the shares[11] Borrowings and Financial Expenses - The company reported a 100% increase in long-term borrowings, totaling ¥9,990,000.00, indicating new financing activities[9] - The company incurred a financial expense of -¥33,918.68, a decrease of 120.01% compared to ¥169,547.94 in the previous year, indicating reduced interest expenses[9] - The company’s short-term borrowings decreased to CNY 232,203,941.37 from CNY 271,951,458.90, a reduction of approximately 14.6%[15] Inventory and Receivables - The inventory increased to CNY 256,586,091.20 from CNY 250,990,855.31, indicating a rise of approximately 2.4%[15] - The accounts receivable decreased to CNY 104,358,811.25 from CNY 113,932,795.48, reflecting a decline of about 8.4%[14] Earnings Per Share - The company’s basic earnings per share improved to -¥0.0280 from -¥0.0303, reflecting a 7.59% increase[5] - Basic and diluted earnings per share were both ¥-0.0280, an improvement from ¥-0.0303[20] Government Subsidies - The company received government subsidies amounting to ¥177,000.00 during the reporting period[6] Research and Development - The company reported a decrease in research and development expenses to ¥4,017,177.20 from ¥4,738,061.55, a reduction of approximately 15.2%[18]

金陵华软科技股份有限公司 独立董事 2024 年度述职报告 （李永军） 作为金陵华软科技股份有限公司（以下简称"华软科技"或"公司"）的独 立董事，本人以维护公司、股东和投资者的利益为原则，根据《公司法》《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号-主板上 市公司规范运作》《金陵华软科技股份有限公司章程》及有关法律、法规的规定 和要求，谨慎、认真、勤勉地行使公司所赋予独立董事的权利和职责。现就本人 2024 年度履行职责情况述职如下： 一、独立董事的基本情况 2、2024 年度，本人以现场或通讯方式亲自参加股东大会 5 次。 （二）董事会专门委员会工作情况 本人李永军，男，1969 年出生，经济学博士，中国国籍，无境外永久居留权。 1990 年起，历任河北省卫生厅职员、辽宁大学经济学讲师。2002 年至今任北京 大学政府管理学院副教授；现任金陵华软科技股份有限公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》规定的独立性要求， 不存在影响独立性的情况。 二、独立董事年度履职概况 （一）出席股东大会及董事会情况 2024 年，本人认真参加了公司的董事会及股东大会， ...